Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

Croma (Croma-Pharma^® GmbH) announced today that it has received marketing authorisation for Letybo^®, the company’s botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Luxembourg, Malta, Norway, Slovakia and Sweden. Letybo^® will be launched in these countries in the coming weeks.